Intermountain Healthcare Selected for Participation in CancerLinQ

SALT LAKE CITY, UTAH, USA, July 14, 2016  -- The American Society of Clinical Oncology (ASCO) has announced the launch of the nation’s largest leading cancer informatics program, CancerLinQ. Intermountain Healthcare is excited to announce its selection as an early adopter of the ASCO CancerLinQ program and its new partnership to share cancer care data. The data-sharing initiative will be used to rapidly improve the quality of care for cancer patients. CancerLinQ is a wholly-owned subsidiary of the American Society of Clinical Oncology (ASCO), who promotes research and education for high quality patient care. 

Intermountain Healthcare offers the largest and most in-depth network of leading cancer specialists in the state of Utah and is also widely renowned for its precision genomics operations that create personalized treatment plans.

Intermountain will partner with affiliated physicians, Utah Cancer Specialists and Utah Hematology Oncology on integrating the information with CancerLinQ.

To date, CancerLinQ links 58 oncology practices in 39 states representing 1,000 providers and 750,000 patient records to the early adopter program. ASCO represents 40,000 of the world’s leading oncologists who comprise ASCO’s membership. 

CancerLinQ works to gather real-time data from cancer patients by way of electronic health records. In turn, CancerLinQ will be able to send feedback to Intermountain providers that compares the care they administer to high-quality guidelines.

All data shared will comply with applicable laws and standards to protect patients’ privacy. Anonymous data will also be used to answer questions regarding effective treatments and cancer prevention from the records of thousands of patients.

The database will bring together a sizeable collaboration of providers, oncologists and medical systems, analyzing over a million cancer patient’s records to find quality care trends. That and to help provide the best possible outcomes for patients. The database will also feed insights to providers on personalized and unbiased treatments and support for every cancer patient and with every type of cancer.